公平贸易委员会起诉 " Optum Rx " 、 " Caremark " 和 " Express Scripts ", 要求增加胰岛素价格,排除价格更便宜的选择。 FTC sues Optum Rx, Caremark, and Express Scripts for inflating insulin prices and excluding cheaper options.
FTC 起诉了美国三大药房福利管理公司 （PBM） — UnitedHealth 的 Optum Rx、CVS 的 Caremark 和 Cigna 的 Express Scripts，指控它们抬高胰岛素价格，以从药品制造商那里获得更高的回扣。 The FTC has sued the three largest U.S. pharmacy benefit managers (PBMs)—UnitedHealth's Optum Rx, CVS's Caremark, and Cigna's Express Scripts—accusing them of inflating insulin prices to secure higher rebates from drug manufacturers. 投诉称,这些PBM排除了更廉价的胰岛素选择,伤害了数百万糖尿病患者。 The complaint alleges these PBMs exclude cheaper insulin options, harming millions of diabetic patients. 这一行动与拜登政府降低药品成本和增加药品定价透明度的努力是一致的。 This action aligns with the Biden administration's efforts to lower drug costs and increase transparency in pharmaceutical pricing.